RxDoctor Payments Data

Dane Ponthier, PA

Medical · Alexandria, LANPI 1285614008

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 230 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by AbbVie at 45.6% of the total. Reporting peaked in 2022 at $1,135 and has fallen 98.5% since, to $17 in 2025.

$3,130in general payments, 2019–2025

Across 230 payments — averaging $13.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$363
  • Corium, LLC$159
  • Tris Pharma Inc$117
  • Novo Nordisk$102
  • Axsome Therapeutics, Inc.$95
  • plus $868 from 18 others

What the payments were for

  • Food & beverage$3,130100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,130 in reported general payments places this provider in the 80th percentile of 253 medical providers in Louisiana.

See all medical providers in Louisiana

Medicare billing

Part B allowed, 2024
$43,490
Medicare patients
347
Services billed
2,071

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide43$42,123
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$18,193
JardianceEmpagliflozin17$14,885
FarxigaDapagliflozin Propanediol13$12,436
Gabapentin76$1,404
SynthroidLevothyroxine Sodium21$1,204
Pantoprazole Sodium87$950
Levothyroxine Sodium79$872
Rosuvastatin Calcium46$870
Azelastine Hcl30$637
Duloxetine Hcl52$626
Potassium Chloride49$624
Omeprazole50$514
Cefdinir27$472
Liothyronine Sodium12$469

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$102$42,12343 claims
GSKTrelegy Ellipta$93$18,19329 claims
Boehringer IngelheimJardiance$32$14,88517 claims
AstraZenecaFarxiga$81$12,43613 claims
AbbVieSynthroid$1,426$1,20421 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 253 medical providers in Louisiana.

Other medical in Alexandria

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →